Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy
GDF-15 is a biomarker for mitochondrial diseases. We investigated the application of GDF-15 as biomarker of disease severity and response to deoxynucleoside treatment in patients with thymidine kinase 2 (TK2) deficiency and compared it to FGF-21. GDF-15 and FGF-21 were measured in serum from 24 patients with TK2 deficiency treated 1-49 months with oral deoxynucleosides. Patients were grouped according to age at treatment and biomarkers were analyzed at baseline and various time points after treatment initiation. GDF-15 was elevated on average 30-fold in children and 6-fold in adults before the start of treatment. There was a significant correlation between basal GDF-15 and severity based on pretreatment distance walked (6MWT) and weight (BMI). During treatment, GDF-15 significantly declined, and the decrease was accompanied by relevant clinical improvements. The decline was greater in the paediatric group, which included the most severe patients and showed the greatest clinical benefit, than in the adult patients. The decline of FGF-21 was less prominent and consistent. GDF-15 is a potential biomarker of severity and of therapeutic response for patients with TK2 deficiency. In addition, we show evidence of clinical benefit of deoxynucleoside treatment, especially when treatment is initiated at an early age.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Scientific reports - 10(2020), 1 vom: 22. Juni, Seite 10111 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dominguez-Gonzalez, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.01.2021 Date Revised 22.06.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-020-66940-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311506585 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311506585 | ||
| 003 | DE-627 | ||
| 005 | 20231226201556.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-020-66940-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311506585 | ||
| 035 | |a (NLM)32572108 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dominguez-Gonzalez, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2021 | ||
| 500 | |a Date Revised 22.06.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a GDF-15 is a biomarker for mitochondrial diseases. We investigated the application of GDF-15 as biomarker of disease severity and response to deoxynucleoside treatment in patients with thymidine kinase 2 (TK2) deficiency and compared it to FGF-21. GDF-15 and FGF-21 were measured in serum from 24 patients with TK2 deficiency treated 1-49 months with oral deoxynucleosides. Patients were grouped according to age at treatment and biomarkers were analyzed at baseline and various time points after treatment initiation. GDF-15 was elevated on average 30-fold in children and 6-fold in adults before the start of treatment. There was a significant correlation between basal GDF-15 and severity based on pretreatment distance walked (6MWT) and weight (BMI). During treatment, GDF-15 significantly declined, and the decrease was accompanied by relevant clinical improvements. The decline was greater in the paediatric group, which included the most severe patients and showed the greatest clinical benefit, than in the adult patients. The decline of FGF-21 was less prominent and consistent. GDF-15 is a potential biomarker of severity and of therapeutic response for patients with TK2 deficiency. In addition, we show evidence of clinical benefit of deoxynucleoside treatment, especially when treatment is initiated at an early age | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a DNA, Mitochondrial |2 NLM | |
| 650 | 7 | |a GDF15 protein, human |2 NLM | |
| 650 | 7 | |a Growth Differentiation Factor 15 |2 NLM | |
| 650 | 7 | |a fibroblast growth factor 21 |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factors |2 NLM | |
| 650 | 7 | |a 62031-54-3 |2 NLM | |
| 650 | 7 | |a thymidine kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a Thymidine Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.1.21 |2 NLM | |
| 700 | 1 | |a Badosa, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Madruga-Garrido, Marcos |e verfasserin |4 aut | |
| 700 | 1 | |a Martí, Itxaso |e verfasserin |4 aut | |
| 700 | 1 | |a Paradas, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Ortez, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz-Manera, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Berardo, Andres |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Pérez, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Trifunov, Selena |e verfasserin |4 aut | |
| 700 | 1 | |a Cuadras, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Kalko, Susana G |e verfasserin |4 aut | |
| 700 | 1 | |a Blázquez-Bermejo, Cora |e verfasserin |4 aut | |
| 700 | 1 | |a Cámara, Yolanda |e verfasserin |4 aut | |
| 700 | 1 | |a Martí, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Mavillard, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Montoya, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Pesini, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Villarroya, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Montero, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Villarroya, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Artuch, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Hirano, Michio |e verfasserin |4 aut | |
| 700 | 1 | |a Nascimento, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez-Mallebrera, Cecilia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 10(2020), 1 vom: 22. Juni, Seite 10111 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:1 |g day:22 |g month:06 |g pages:10111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-020-66940-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 1 |b 22 |c 06 |h 10111 | ||